Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
C1 esterase inhibitor concentrates
11 evidence topics · 9 sources
Plasma-derived C1 inhibitor: indication, dose, and self-administration
Plasma-derived C1 inhibitor: laryngeal attacks, thromboembolism, and infectious risk
Plasma-derived C1 inhibitor 20 IU/kg versus placebo: randomized clinical trial in the label
Plasma-derived C1 inhibitor 10 or 20 U/kg versus placebo: published randomized trial in 125 participants
“This was a randomized, double-blind, placebo-controlled study in 125 patients with type I or II hereditary angioedema.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median time to onset of relief was significantly shorter with C1 esterase inhibitor concentrate at a dose of 20 U/kg than with placebo (0.5 vs 1.5 hours; P = .0025), whereas with 10 U/kg, the time to onset of relief was only slightly shorter than with placebo (1.2 vs 1.5 hours; P = .2731).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with placebo, the reduction in time to onset of relief was greatest for severe attacks (0.5 vs 13.5 hours).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Plasma-derived C1 inhibitor for laryngeal attacks: open-label extension in the label
Recombinant human C1 inhibitor: indication, dose, redosing limit, and contraindication
Recombinant human C1 inhibitor 50 U/kg versus placebo: Study 1 in the label
“Seventy-five patients experiencing peripheral, abdominal, facial, and/or oropharyngeal laryngeal attacks were randomized (3:2) to rhC1INH (n = 44) or placebo (saline; n = 31).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median (95% confidence interval) time to beginning of symptom relief at the primary attack location was 90 minutes (61-150) in rhC1INH-treated patients vs 152 minutes (93, not estimable) in placebo-treated patients (P = .031) based on the TEQ” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, rhC1INH was safe and well tolerated; no thromboembolic events, anaphylaxis, or neutralizing antibodies were observed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Recombinant human C1 inhibitor 50 or 100 U/kg versus saline: pooled analysis of two randomized trials
“Two similar independent, randomized, saline controlled, double-blind studies were conducted to evaluate the efficacy and safety of recombinant human C1-inhibitor (rhC1INH) as a treatment of acute angioedema attacks in patients with HAE.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“rhC1INH at 100 (n = 29) and 50 (n = 12) U/kg body weight resulted in a significant reduction for both the primary endpoint time to the beginning of relief of symptoms compared with saline (n = 29): median, 66 (95% CI, 61-122) minutes, 122 (72-136) minutes, and 495 (245-520) minutes, P < .001 and P = .013, respectively” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Therapeutic failure occurred in 59% (17/29) of the saline group compared with 0% (0/12) of the 50 U/kg group and 10% (3/29) of the 100 U/kg group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Intravenous C1 inhibitor as a first-line on-demand treatment: guideline recommendations
“Four types of ODT for HAE attacks are recognized as effective: exogenous intravenous (IV) C1-INH (plasma-derived [pdC1-INH] or recombinant [rC1-INH]), icatibant, sebetralstat, and ecallantide” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that first-line ODT for HAE attacks include either IV C1-INH, icatibant or sebetralstat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is commercially available in 2 plasma-derived concentrates and 1 recombinant human product for intravenous administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that attacks are treated with either intravenous C1 inhibitor, ecallantide, or icatibant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For on-demand treatment, only the intravenous application of C1–INH is effective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose rounding, half-life, and rabbit allergy: guideline statements
“When pdC-1INH is used, it should be administered at a dose of 20 IU/kg, rounded to the nearest 500 IU (as vials contain 500 IU) to minimize product waste.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“rC1-INH is produced through genetic engineering, and because it is secreted in the milk of transgenic rabbits, it is contraindicated in patients with a known allergy to rabbits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean plasma half-life of pdC1-INH is longer than 30 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It appears that differential glycosylation of Ruconest relative to the human protein decreases the plasma half-life to approximately 3 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma-derived C1 inhibitor in pregnancy and in children: guideline recommendations
“Plasma-derived C1-INH is considered safe and effective for on-demand treatment of HAE attacks during pregnancy, whereas all other drugs are off-label alternatives.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For pregnant patients with HAE, we recommend first-line ODT with IV pdC1-INH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In neonates and infants with hereditary angioedema due to C1 inhibitor deficiency between birth and 2 years, we recommend the use of intravenous plasma‐derived C1 inhibitor concentrate as first‐line therapy for acute treatment of angioedema attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In children with hereditary angioedema due to C1 inhibitor deficiency aged between 2 and 12 years, we recommend the use of icatibant, intravenous plasma‐derived C1 inhibitor concentrate, or intravenous recombinant human C1 inhibitor as first‐line therapy for acute treatment of angioedema attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote